Update: October 2018
Longidase is an effective enzyme preparation with
proteolytic, i.e. protein cleavage action as well
immunomodulatory, anti-inflammatory and antioxidant
activity. The drug has a long therapeutic
Two active components in the composition of the drug – azoksimera bromide
and hyaluronidase, lead to the following positive effects:
- improved tissue permeability;
- trophic enhancement;
- resorption of hematomas;
- reduction of edema;
- increase tissue elasticity;
- the disappearance of adhesions and contractures;
- increased joint mobility;
- suppression of connective tissue growth in scars.
Longidase can bind heavy metals and neutralize
toxins. The drug does not cause carcinogenic, mutagenic,
toxic and embryotoxic action on the body and well
tolerated by patients – according to reviews, injections and Longidase candles do not give
Фармгруппа: Препараты с протеолитической activity.
The composition of the drug, physico-chemical properties and price
The drug is produced in two dosage forms: suppositories
(method of administration rectally or vaginally) and lyophilisate for
obtain a solution of subcutaneous or intramuscular injection.
|Main substance||Longidase with hyaluronidase activity: 3000 IU||Longidase with hyaluronidase activity of 1500 IU (ampoules and
bottles of 1500 IU) or 3000 IU ampoules and bottles of 3000 IU)
|Excipients||Cacao butter||Mannitol 15 mg (vials and ampoules 1500 IU) or 20 mg (ampoules and
vials 3000 IU)
|Physicochemical properties||Candles elongated, yellowish, with a faint odor
cocoa butter. Marble coloring of the suppository is acceptable.
|Porous hygroscopic mass having a white or white and yellow
|Packaging||On 5 suppositories in contour cells, enclosed in cardboard
|On 5 ampoules or bottles in cellular packings enclosed in
The drug has a prolonged enzymatic
proteolytic action. Prolongation of action occurs
due to covalent longidase binding to high molecular weight,
active carrier (derived N-oxide
poly-1,4-ethylene piperazine), which possesses pharmacological
Covalent bond ensures enzyme resistance to
destructive reactions and the action of inhibitors, as well as simultaneous
local presence of carrier and hydrolytic enzyme,
binding enzyme inhibitors and collagen synthesis activators
(ions of copper, iron, heparin). That is why Longidase is capable
depolymerise the connective tissue matrix in
fibro-granulomatous structures, as well as suppress regulatory
the reaction necessary to synthesize the structural units
Glycosaminoglycans, such as chondroitin, hyaluronic acid,
chondroitin-4 and -6-sulphate are specific substrates
hyaluronidase testicular. They form the basis
connective tissue matrix. As a result of depolymerization under
the influence of hyaluronidase substrates lose their properties, such as
ability to bind water, viscosity, etc. Also difficult
the conversion of collagen protein into fiber is enhanced
permeability of tissue barriers, improves the movement of fluid between
cells and ultimately improves the elasticity of the connective
Longidase helps to reduce the manifestations of the acute phase
inflammation, affects the synthesis of inflammatory mediators,
increases infectious resistance and increases tension
When parenteral route of administration quickly enters the system
blood flow, reaching maximum concentration in 20-25 minutes.
It is quickly distributed through tissues, penetrates into all organs and
structures, including the brain, but not cumulated.
With rectal and vaginal administration also quickly falls into
blood flow, reaching maximum concentration after 1 h.
The bioavailability of suppositories is 70%. Excreted by the kidneys
(elimination half-life makes 42-84 h). Metabolized to
low molecular weight oligomers.
Indications for use
Used in the treatment of children from 12 years and adults
with pathologies occurring with connective tissue hyperplasia.
It is also prescribed to improve the bioavailability of diagnostic and
|Pulmonology, gynecology and urology during development
interstitial inflammatory response:
Orthopedics, surgery, cosmetology:
- Malignant tumors;
- Children’s age up to 12 years;
- Hypersensitivity to Longidase and other drugs with
With a lack of renal function and pulmonary bleeding earlier
– Appoint no more than 1 time per week.
The method of administration and dosing is carried out individually,
based on the severity, the clinic of pathology and the age of the person.
According to the instructions for use Longidase injections indicated that
Requires preliminary preparation of the solution. Bottle Contents
or ampoules are dissolved in one and a half to two ml of 0.25% or 0.5% p-ra
procaine or in 0.9% NaCl solution, water for injection with
procaine intolerance. The solution can not be stored, therefore introduced
immediately cooking field.
Injected subcutaneously near the affected tissue or / m in a dosage of 3000
IU In total, 5-15 injections are prescribed with a time interval between
every 3-10 days. Repeated course – in 2-3 months.
With pathologies with severe chronic productive process
nature of the connective tissue after treatment is assigned
maintenance therapy of 3000 IU in 10-14 days.
To improve the bioavailability of other drugs: 1500 IU once
after 3 days, the total number of injections should not exceed 10.
Recommended treatment regimens
- Pathology of the respiratory system: 3000 IU once in 3-5 days –
total 10 intramuscular injections. Maintenance treatment: 3000 each
IU once in 10-14 days (up to 12 months).
- Pathology of the pelvic organs: 3000 IU once every 3-5
days course of 5-15 intramuscular injections.
- Scleroderma: 3000-4500 IU once in 3 days in a course of 5-15
- Scars: 3000 IU inside the rumen in a dose of one to two times a week 5-10
injection or 3000 IU once every 3-5 days – only 10
- Non-scarring wounds: 1500-3000 IU once in 5 days
курсом 5-7 intramuscular injection.
- Arthritis, contractures, hematomas: 3000 IU once or twice a week
7-15 intramuscular injection.
- Adhesive disease: 3000 IU once in 3-5 days 7-15
Candles Longidase: instructions for use
Appointed for rectal or intravaginal administration.
once a day for the night course of 10-20 candles. For rectal
administration is recommended to introduce a candle after emptying the bowel.
With intravaginal administration – injected in the supine position.
- Urology: по 1 свече через 1 день 10 введений, затем через 2-3
days – 10 more introductions.
- Gynecology: по 1 свече через двое суток — 10 введений.
- Dermatovenereology: по 1 свече через один-два дня. On course
- Surgery: по 1 свече через два-три дня. On course 10 свечей.
- Pulmonology and phthisiology: 1 candle in two to four days. On
course of 10-20 suppositories. Supportive treatment – 1 candle
once a week for 3-4 months
- Local: pain at the injection site, rarely – hyperemia and
skin swelling. When using candles occasionally itching and
puffiness at the injection site.
- Allergic reactions are rarely possible.
- All side effects pass after 48-72 h.
Reduced Longidase activity while treating
estrogens, salicylates, cortisone, ACTH, antihistamine drugs in
high doses. Consideration should be given to increasing the bioavailability of the second
drug at simultaneous use with Longidaza.
Longidase should not be injected into an acute or infectious area.
lesions. In the treatment of acute foci of infection at the same time
prescribe antimicrobial agents.
With the development of any allergic reaction, the drug is canceled.
Such cases are not recorded.
Lidaza (10 amp. 200 rub), Lidaza – M and
Автор: врач-гигиенист, эпидемиолог